Glaukos (GKOS) Expected to Release Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) will likely be announcing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of ($0.0964) per share and revenue of $168.04 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The business had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same period in the prior year, the company earned ($0.24) EPS. Glaukos’s revenue for the quarter was up 49.6% on a year-over-year basis. On average, analysts expect Glaukos to post ($0.32) EPS for the current fiscal year and $0.55 EPS for the next fiscal year.

Glaukos Trading Up 0.1%

GKOS stock opened at $179.02 on Monday. The business has a fifty day moving average price of $171.35 and a 200 day moving average price of $150.46. Glaukos has a fifty-two week low of $73.16 and a fifty-two week high of $191.62. The stock has a market capitalization of $10.56 billion, a price-to-earnings ratio of -55.08 and a beta of 0.69. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Wells Fargo & Company boosted their price objective on Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Jefferies Financial Group raised their target price on Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Citigroup lifted their price target on Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, October 15th. Finally, UBS Group started coverage on shares of Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price target on the stock. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $181.43.

Insider Activity at Glaukos

In other Glaukos news, Director Leana Wen sold 525 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $167.63, for a total transaction of $88,005.75. Following the transaction, the director owned 21,092 shares of the company’s stock, valued at approximately $3,535,651.96. This represents a 2.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joseph Gilliam sold 60,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 83,025 shares of company stock worth $14,950,006. 5.90% of the stock is currently owned by company insiders.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.